

# Medical Science

## To Cite:

Krych G, Skóra M, Kazimierski B, Rusak A, Oklińska J, Jadczyk K, Gniado W, Mądry D. Vortioxetine - a new antidepressant drug with multimodal action – Review of recent studies. *Medical Science* 2026; 30: e82ms3873  
doi: <https://doi.org/10.54905/disssi.v30i171.e82ms3873>

## Authors' Affiliation:

<sup>1</sup>Provincial Complex Hospital named after Jędrzej Śniadecki in Białystok, ul. M. Curie-Skłodowskiej 26, 15-950 Białystok, Poland

<sup>2</sup>The Nicolaus Copernicus Municipal Polyclinical Hospital in Olsztyn, ul. Niepodległości 44, 10-045 Olsztyn, Poland

<sup>3</sup>University Clinical Hospital in Białystok, ul. M. Curie-Skłodowskiej 26, 15-276 Białystok, Poland

## \*Corresponding author:

Gabriela Krych,

Provincial Complex Hospital named after Jędrzej Śniadecki in Białystok, ul. M. Curie-Skłodowskiej 26, 15-950 Białystok, Poland,

ORCID: 0009-0005-6873-5358,

E-mail: [krych55@gmail.com](mailto:krych55@gmail.com),

Phone: +48-662-065-644.

## ORCID List:

Gabriela Krych	0009-0005-6873-5358
Michał Skóra	0009-0001-5137-9490
Bartłomiej Kazimierski	0009-0007-4480-5440
Aleksandra Rusak	0009-0006-7366-3368
Joanna Oklińska	0009-0001-5779-0539
Klaudia Jadczyk	0000-0002-2214-8319
Weronika Gniado	0009-0002-5676-3456
Dawid Mądry	0009-0003-5948-4548

## Peer-Review History

Received: 29 May 2025

Reviewed & Revised: 16/June/2025 to 18/April/2026

Accepted: 25 April 2026

Published: 07 May 2026

## Peer-review Method

External peer-review was done through double-blind method.

Medical Science

pISSN 2321–7359; eISSN 2321–7367



© The Author(s) 2026. Open Access. This article is licensed under a [Creative Commons Attribution License 4.0 \(CC BY 4.0\)](https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

# Vortioxetine - a new antidepressant drug with multimodal action – Review of recent studies

Gabriela Krych<sup>1\*</sup>, Michał Skóra<sup>1</sup>, Bartłomiej Kazimierski<sup>1</sup>, Aleksandra Rusak<sup>2</sup>, Joan-na Oklińska<sup>1</sup>, Klaudia Jadczyk<sup>3</sup>, Weronika Gniado<sup>1</sup>, Dawid Mądry<sup>1</sup>

## ABSTRACT

Vortioxetine is among the new antidepressant drugs. Unlike traditional antidepressants that focus on a single mechanism of action, it is a multimodal drug that improves cognitive function and has antidepressant and anti-anxiety effects. More recently, it has attracted attention for its ability to reduce discomfort in neuropathic pain by modulating descending inhibitory pathways in the spinal cord. Experts recognize vortioxetine as one of the most effective and best-tolerated options. The pharmacodynamic profile and clinical studies of this drug lead researchers to believe that its mechanism of action consists primarily of direct modulation of serotonin receptor activity (e.g., 5-HT<sub>3</sub>, 5-HT<sub>7</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>1B</sub>) and selective inhibition of SERT (serotonin reuptake). Thus, this drug significantly alters the way in which two or more serotonin receptors interact.

**Keywords:** vortioxetine, depression, cognitive function, neuropathic pain, antidepressants

## 1. INTRODUCTION

In the mid-1990s, following the successful dissemination of selective serotonin reuptake inhibitors, pharmaceutical companies became interested in preclinical and clinical studies on serotonin transporter (SERT) inhibition and somatodendritic serotonin 1A (5-HT<sub>1A</sub>) auto-receptor antagonism. The results showed an earlier and significantly greater increase in non-cellular serotonin levels in the brains of rodents, resulting in higher efficacy and shorter duration of action than selective serotonin reuptake inhibitor (SSRI) drugs. Developing a drug with SERT and 5-HT<sub>1A</sub> mechanisms proved very challenging, especially in determining the optimal potency ratio between the two mechanisms and the optimal activity at the 5-HT<sub>1A</sub> receptor. During drug development, researchers redirected the target profile to achieve a combination of 5-HT<sub>1A</sub> receptor agonism, SERT inhibition, and 5-HT<sub>3</sub> receptor antagonism. They thought that 5-HT<sub>3</sub> receptor antagonism would result in a lower rate of nausea and/or vomiting, an adverse effect of SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs).

Vortioxetine was approved as a drug in the autumn of 2013 by the FDA and EMA for the treatment of major depression. The FDA and EMA approved

Vortioxetine as a drug in the autumn of 2013 for the treatment of major depression (Sowa-Kućma et al., 2017). Re-searchers have extensively studied the drug, and every year, there is more and more data supporting its safety and high efficacy in treating major depression (Cipriani et al., 2018).

### Aim of the study

The review will provide useful information related to the drug, including its mechanisms of action, side effects, clinical applications, and its distinct multimodal mechanism of action. Vortioxetine has efficacy for treating major depressive disorder (MDD) and generalized anxiety disorder (GAD), as well as an increasingly recognized role in enhancing cognitive function and managing neuropathic pain.

## 2. REVIEW METHODS

This review follows a defined methodology to provide a complete and honest assessment of the pharmacological and clinical characteristics of vortioxetine. All literature reviewed was peer-reviewed and freely available online; major sources included PubMed, Google Scholar, and healthcare websites (e.g., hospitals, universities). Vortioxetine comprehensively searched for and excluded articles that did not have an online full text published. All conclusions drawn from the articles examined are based on the currently available literature and scientific and clinical guidelines; thus, all of our work accurately reflects the current state of medical advancement. The screening process of the articles follows the PRISMA guidelines (Figure 1).




Figure 1. PRISMA CONSORT chart

### 3. RESULTS & DISCUSSION

#### Structure and mechanism of action

Vortioxetine is a drug that is chemically named 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl] piperazine. The molecular weight is 298.45 g/mol. We can describe the drug's mechanism of action as multimodal, as it has multiple mechanisms: SERT inhibition and direct modulation of various serotonin receptors, including 5-HT<sub>1A</sub> receptor agonism, 5-HT<sub>1B</sub> receptor partial agonism, and 5-HT<sub>3</sub>, 5-HT<sub>1D</sub>, and 5-HT<sub>7</sub> receptor antagonism. Therapeutic doses (5-20 mg/day) used in humans correspond to 50-80% SERT occupancy. Pre-clinical studies have shown that it affects the activity of multiple systems, including 5-HT, norepinephrine, histamine, dopamine, glutamate, acetylcholine, and GABA (Sowa-Kučma et al., 2017). In scientific studies using progesterone withdrawal and tryptophan depletion, the mechanisms of action of vortioxetine beyond SERT inhibition are important for explaining the drug's antidepressant effect (Li et al., 2013; Hlavacova et al., 2018).

Researchers highlight the significant role of glutamatergic signaling and neuroplasticity in the pathophysiology of depression and the effectiveness of antidepressants (Du Jardin et al., 2016). In postmortem studies, lower neuronal density and size, as well as reduced glial cell and dendrite abundance, were observed in the frontal cortex and hippocampus of patients with major depressive disorder (Rajkowska et al., 1999). A detailed review and exploration of the mechanisms of action suggest that 5-HT<sub>3</sub> receptor blockade is one of the most important properties of vortioxetine for improving cognitive function, as observed in clinical trials (Bennabi et al., 2019).

The modulating effects of neurotransmitters, i.e., dopamine, norepinephrine, histamine, or acetylcholine, in the medial prefrontal cortex, and the enhancement of neurogenesis and, most importantly, neurotrophic processes in the hippocampus are considered additional mechanisms contributing to the procognitive effects of vortioxetine. Studies have shown that vortioxetine causes spectral changes in quantitative electroencephalography (qEEG) that differ from those of SNRIs and SSRIs. In particular, the effect of vortioxetine, in contrast to escitalopram and duloxetine, on increases in cortical frequency ranges was highlighted, which may play a significant role in improving cognition (Leiser et al., 2014). The potent 5-HT<sub>3</sub> antagonism prompted the testing of vortioxetine in animal models of neuropathic pain. Studies have shown that 5-HT<sub>3</sub> receptors are actively involved in the pathophysiology of neuropathic pain (Ossipov et al., 2010). In addition, vortioxetine has shown immunomodulatory effects, including antioxidant and anti-inflammatory, which may result in clinical benefits (Talmon et al., 2018). Moreover, vortioxetine has better anti-inflammatory effects than other antidepressants (Tomaz et al., 2020).

Thus, vortioxetine has multiple mechanisms of action that regulate different neurotransmitters. Vortioxetine not only offers patients the advantages of an antidepressant but also enhances cognition, alleviates pain, and reduces inflammation (Talmon et al., 2018; Salagre et al., 2018).

#### Pharmacokinetics

Vortioxetine is a slowly absorbed drug that peaks after about 8 hours. Consumption of a meal does not affect the absorption process. The drug's pharmacokinetics are linear. The half-life is 2.75 days, and the steady state (the state in which the rate and amount of drug entering the body equals the rate and amount of drug leaving) is about 2 weeks. It is a drug that binds strongly to proteins. It has the potential to interact with other drugs that also bind to proteins. Vortioxetine undergoes hepatic metabolism primarily via cytochrome P450 isozymes, primarily CYP2D6, with CYP3A4/5 also contributing. For this reason, one must be careful and mindful of drug interactions with CYP 2D6 inhibitors (i.e., fluoxetine, paroxetine, quinidine, and bupropion) and CYP 3A4/5 inducers (i.e., carbamazepine), among others. There are also possible interactions with serotonergic drugs (risk of serotonin syndrome) and drugs that increase bleeding (i.e., aspirin, warfarin). Vortioxetine is a drug with no active metabolites (Keks et al., 2015)

#### Pharmacodynamics

Clinical studies in rats have shown that vortioxetine's potency at serotonin receptors is not uniform. The order of action on different 5-HT receptor elements in the ranking is as follows: 5-HT<sub>3</sub> > SERT > 5-HT<sub>1B</sub> > 5-HT<sub>1A</sub> ≈ 5-HT<sub>7</sub>. An electroencephalographic (EEG) study showed that vortioxetine, compared with escitalopram and duloxetine, selectively increased frontal cortex impulsivity and oscillatory activity. Researchers did not observe these effects with the tested SSRI and SNRI group drugs. They believe that cortical activation results from the agonism of 5-HT<sub>1A</sub> receptors and the antagonism of 5-HT<sub>3</sub> and 5-HT<sub>7</sub> receptors. Such effects help improve cognitive function in depressed patients (Gonda et al., 2019).

### Breastfeeding

The level of vortioxetine in breast milk, based on scientific studies, is low. The study evaluated vortioxetine levels in breastfeeding mothers and drug concentrations in milk at 5 time points within 24 hours (Marshall et al., 2021). In another scientific study, re-searchers observed infants whose mothers were breastfeeding and taking vortioxetine. None of the mothers reported unusual behavior in the infant (Monfort et al., 2021). In conclusion, vortioxetine is a drug that appears in breast milk in low concentrations and is relatively safe. If the mother requires the drug, then it should not be discontinued, or breastfeeding should be interrupted. Since there are not many clinical data available, caregivers should approach breastfeeding with caution and carefully observe the infant and their development.

### Side Effects

Common side effects include nausea, dizziness, constipation, drowsiness, and dry mouth. Of the far rarer side effects, we can distinguish mood disorders, suicidal thoughts, serotonin syndrome, increased risk of bleeding, or hypersensitivity reactions. Hypersensitivity reactions to the drug include rash, eosinophilia, and fever. Elevated liver enzymes may occur during treatment with vortioxetine, although this occurs in less than 1% of cases. Elevations in liver enzymes are self-limiting and do not require a change in dose or treatment. Starting at 10 mg/day, increasing to 20 mg/day based on the patient's efficacy and tolerability. Lower doses, i.e., 5 mg once daily, can be used when adverse effects of the drug are present. Side effects of the drug can also include sexual dysfunction (ejaculatory and erectile dysfunction, abnormal orgasm, or decreased libido).

Gender matters in this case, as during treatment, it is men who have a higher risk of experiencing side effects in the form of sexual disorders. Interestingly, this type of disorder was reported more frequently with the 2.5 mg dose compared to the 5 mg dose (Faquih et al., 2019). Vortioxetine does not affect blood pressure or cardiovascular risk (Calvi et al., 2021). Moreover, the risk of QT interval prolongation during therapy is minimal (Kahl et al., 2022). Vortioxetine can cause hyperprolactinemia and galactorrhea in some patients. Interestingly, vortioxetine is a safe drug and well-tolerated after alcohol consumption. Patients with liver dysfunction can receive it without restriction.

### Depression

Depression is one of the most common and debilitating conditions worldwide. Many episodes of depression go unrecognized. Women are 3 times more likely to suffer from depression than men. Relapses characterize major depression, and their risk is higher after another relapse. The median onset of depression is 25 years, and an initial episode as well as a relapse can occur at any age. Patients with depression have a high level of functional disability, greater than those with hypertension, diabetes, or coronary artery disease. Most patients come to the doctor with somatic symptoms, i.e., unexplained pain, gastrointestinal symptoms, or headache. Many complain of extreme fatigue. Few initially mention the axial symptoms of depression, i.e., sadness, depression, or lack of motivation (Rakel, 1999).

The effectiveness of vortioxetine in treating depression has been confirmed in both short-term (6-8 weeks) and long-term (up to 52 weeks) studies. It has broad positive effects on physical, emotional, and cognitive symptoms (De Diego-Adeliño et al., 2022). Many studies have confirmed the effectiveness of drugs in treating major depression. Moreover, increasing doses of vortioxetine (5-20mg/day) have been associated with greater efficacy (Thase et al., 2016). Vortioxetine in depression has shown high efficacy in treating anhedonia, defined as an impaired ability to experience pleasure. The drug's efficacy has been associated with improvements in functioning and overall quality of life (Cao et al., 2019). Placebo-controlled studies have sought to determine the effect of vortioxetine in alleviating somatic symptoms associated with depression, i.e., headaches, muscle tension, sleep disturbances, appetite, or sexual dysfunction. These symptoms are often present in a depressive episode, including chronic symptoms, and often co-occur with anxiety disorders. Vortioxetine effectively relieves most somatic symptoms, even in individuals with high levels of anxiety. Vortioxetine doesn't increase the risk of suicide in adults with major depression (De Diego-Adeliño et al., 2022).

### Generalized anxiety disorder

Generalized anxiety disorder (GAD) impairs a patient's daily functioning. People with Generalized Anxiety Disorder (GAD) experience worse psychosocial functioning than individuals who have recently suffered a heart attack or congestive heart failure. Their impaired functioning resembles that of someone experiencing a major depressive episode. Those with GAD frequently exhibit somatic symptoms of anxiety, including sleep disturbances, irritability, restlessness, muscle tension, and fatigue. Additionally, they often experience cognitive dysfunction, characterized by deteriorating attention and reduced concentration. Such patients often worry that they or a loved one will become ill, have an accident, or die. In randomized clinical trials, vortioxetine is well tolerated and highly effective in the

treatment of GAD. Clinicians should exercise caution in practice because the number of studies is limited. Well-designed studies comparing the efficacy of vortioxetine to other antidepressants are still lacking (Pae et al., 2015).

**Cognitive disorders**

Cognitive impairment in depression isn't just in one area; it's a broad spectrum (im-pacting executive function, memory, and processing speed), especially in geriatric popula-tions. These deficits do not always resolve alongside mood improvements and can linger as residual symptoms even once a patient enters remission. (Lee et al., 2012). In a meta-analysis, vortioxetine was the drug that produced the greatest improvement in the digital symbol substitution test, which is a neurocognitive test that integrates multiple domains af-fected in depressed patients. Vortioxetine proved to be the only antidepressant drug that significantly induced changes in this test. Vortioxetine showed cognitive-enhancing effects in both older and younger subjects. The greater the baseline functional dysfunction, the greater the improvement with the treatment. Interestingly, the improvement in cognitive function was independent of the antidepressant effect (Baune et al., 2018).

Data on the drug's efficacy in Alzheimer's disease are sparse, but it appears to show greater efficacy in improving neuropsychiatric symptoms compared to placebo with cognitive training or other antidepressants (Cumbo et al., 2019). Underlying the positive effects pro-duced by vortioxetine are 5-HT3 or 5-HT7 antagonism, or 5-HT1A and 5-HT1B agonism, effects on other neurotransmitter systems, or hippocampal neuroplasticity. Direct effects on frontal-limbic networks have also been generally demonstrated (Bennabi et al., 2019).

**Table 1.** Summary of Vortioxetine.

Category	Key Details & Findings
<b>Drug Classification</b>	Multimodal antidepressant.
<b>Mechanism of Action</b>	<b>SERT Inhibition:</b> Selective serotonin reuptake inhibition.  <b>Receptor Modulation:</b> 5-HT1A (agonist), 5-HT1B (partial agonist), 5-HT3, 5-HT1D, and 5-HT7 (antagonist).
<b>Primary Indications</b>	Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD).
<b>Secondary Benefits</b>	<b>Cognitive Function:</b> Improves executive function, memory, and processing speed (independent of mood improvement).  <b>Neuropathic Pain:</b> Modulates descending inhibitory pathways in the spinal cord.  <b>Anti-inflammatory:</b> Shows antioxidant and immunomodulatory effects.
<b>Pharmacokinetics</b>	<b>Absorption:</b> Peak ~8 hours (not affected by food).  <b>Half-life:</b> 2.75 days (steady state reached in ~2 weeks).  <b>Metabolism:</b> Hepatic via CYP2D6 (primary) and CYP3A4/5.
<b>Common Side Effects</b>	Nausea (most common), dizziness, constipation, dry mouth, and drowsiness.
<b>Safety Highlights</b>	Low risk of QT interval prolongation; well-tolerated with alcohol; safe for patients with liver dysfunction; minimal suicidal risk in adults.
<b>Sexual Dysfunction</b>	Risk of ejaculatory/erectile dysfunction and decreased libido; higher risk in men.
<b>Special Populations</b>	<b>Elderly:</b> First-line choice due to cognitive benefits and safety profile.  <b>Breastfeeding:</b> Found in low concentrations in breast milk; generally considered safe but requires infant observation.

## Neuropathic pain

Neuropathic pain has a very high prevalence worldwide, and its treatment is still not satisfactory to an adequate degree, probably due to the elaborate pathomechanism of the pain, which is still not fully understood (Alles and Smith, 2018; McWilliams and Walsh, 2017). Patients with this condition mainly complain of burning sensations and pain elicited by non-painful stimuli (i.e., light touch) (Colloca et al., 2017). Chronic neuropathic pain is a complex phenomenon with both emotional and perceptual components. It often co-occurs with depression, anxiety, and sleep disorders (Yalcin et al., 2014). For this reason, special attention should be paid not only to analgesic treatment but also to the treatment of potentially comorbid conditions and psychiatric disorders (Colloca et al., 2017).

Clinicians place special emphasis on using antidepressants for neuropathic pain, such as specifically tricyclic antidepressants (TCAs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), and selective serotonin reuptake inhibitors (SSRIs). These drugs act as neuromodulators in the central nervous system and are effective simultaneously in relieving pain and controlling anxiety, depression, and sleep quality (Attal et al., 2010). Vortioxetine, classified as an "other antidepressant," effectively treats neuropathic pain. Evidence suggests that pain inhibition requires the involvement of multiple endogenous neurotransmitters, including opioids, cannabinoids, and serotonin. In the case of serotonin, special attention must be paid to the induction of analgesia via activation of 5-HT<sub>7</sub> receptors and hyperalgesia via activation of 5-HT<sub>3</sub> receptors (Nicholson and Verma, 2004).

Researchers have demonstrated that vortioxetine effectively treats pain hypersensitivity and mood disorders through its multimodal action in both experimental and clinical studies. During the drug's action, there is inhibition of SERT, antagonism of serotonin 5-HT<sub>3</sub>, 5-HT<sub>1D</sub>, and 5-HT<sub>7</sub> receptors, and agonism of 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptors. In the clinical trials performed, vortioxetine has shown efficacy in treating patients with chronic facial pain. Moreover, compared with other antidepressants, higher clinical response and remission rates, as well as better acceptability, tolerability, and safety, were observed. Given the new findings, it is worth considering vortioxetine as a drug for neuropathic pain, especially with the co-occurrence of cognitive impairment and depression (Adamo et al., 2021). A summary of this review is provided in Table 1.

## 4. CONCLUSION

Vortioxetine is a new drug mainly used for the treatment of depression, especially one of high severity. It shows additional cognitive-enhancing effects, so it is one of the first-line medications indicated for older people with depression. Side effects are rare, making it a safe choice, especially for older people burdened with other diseases. Its mechanism of action is unique - it modulates and stimulates serotonin transmission. More and more studies are emerging to confirm its efficacy as a neuropathic pain treatment by modulating the descending inhibitory pathways in the spinal cord and generalized anxiety disorder. Randomized controlled trials are still necessary to establish the drug's efficacy for the indication and to examine its safety profile.

### Acknowledgments

We thank all participants who contributed to the studies included in this systematic review. We also acknowledge the support of our institution and colleagues who guided manuscript preparation.

### Authors' Contributions

Conceptualization, supervision, and project administration: Michał Skóra, Gabriela Krych.

Methodology: Klaudia Jadczyk, Bartłomiej Kazimierski, Weronika Gniado

Software, validation, formal analysis, investigation, resources, writing original draft preparation: Weronika Gniado, Aleksandra Rusak, Dawid Mądry.

Writing, review editing, and visualization: Michał Skóra, Gabriela Krych.

All authors have read and agreed with the published version of the manuscript.

### Informed consent

Not applicable.

### Ethical approval

Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors.

**Funding**

This research did not receive any external funding like specific grant from funding agencies in the public, commercial, or nonprofit sectors.

**Conflict of interest**

The authors declare that they have no conflicts of interest, competing financial interests or personal relationships that could have influenced the work reported in this paper.

**Data and materials availability**

All data associated with this study will be available based on the reasonable request to corresponding author.

**REFERENCES**

- Adamo D, Calabria E, Coppola N, Pecoraro G, Mignogna MD. Vortioxetine as a new front-tier in the treatment of chronic neuropathic pain: a review and update. *Ther Adv Psychopharmacol* 2021;11:20451253211034320.
- Alles SRA, Smith PA. Etiology and Pharmacology of Neuropathic Pain. *Pharmacol Rev* 2018;70(2):315-47.
- Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guide-lines on the pharmacological treatment of neuropathic pain: 2010 revision. *Eur J Neurol* 2010;17(9):1113-e88.
- Baune BT, Brignone M, Larsen KG. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder. *Int J Neuropsychopharmacol* 2018;21(2):97-107.
- Bennabi D, Haffen E, Van Waes V. Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research. *Front Psychiatry* 2019;10:771.
- Calvi A, Fischetti I, Verzico I, Belvederi Murri M, Zanetidou S, Volpi R, Coghi P, Tedeschi S, Amore M, Cabassi A. Antidepressant Drugs Effects on Blood Pressure. *Front Cardiovasc Med* 2021;8:704281.
- Cao B, Park C, Subramaniapillai M, Lee Y, Iacobucci M, Mansur RB, Zuckerman H, Phan L, McIntyre R. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder. *Front Psychiatry* 2019;10:17.
- Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018;391(10128):1357-66.
- Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman R, Truini A, Attal N, Finnerup N, Eccleston C, Kalso E, Bennett DL, Dworkin RH, Raja SN. Neuropathic pain. *Nat Rev Dis Primers* 2017;3:17002.
- Cumbo E, Cumbo S, Torregrossa S, Migliore D. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study. *J Prev Alzheimers Dis* 2019;6(3):192-7.
- De Diego-Adeliño J, Crespo JM, Mora F, Neyra A, Iborra P, Gutiérrez-Rojas L, Salonia SF. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. *Expert Opin Drug Saf* 2022;21(5):673-90.
- du Jardin KG, Müller HK, Sanchez C, Wegener G, Elfving B. A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex. *Eur J Pharmacol* 2016;786:29-35.
- Faqui AE, Memon RI, Hafeez H, Zeshan M, Naveed S. A Review of Novel Antidepressants: A Guide for Clinicians. *Cureus* 2019;11(3):e4185.
- Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. *Expert Opin Drug Discov* 2019;14(1):81-9.
- Hlavacova N, Li Y, Pehrson A, Sanchez C, Bermudez I, Csanova A, Jezova D, Franklin M. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. *Prog Neuropsychopharmacol Biol Psychiatry* 2018;82:332-8.
- Kahl KG, Stapel B, Correll CU. Psychological and Psychopharmacological Interventions in Psychocardiology. *Front Psychiatry* 2022;13:831359.
- Keks NA, Hope J, Culhane C. Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor? *Australas Psychiatry* 2015;23(3):210-3.
- Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. *J Affect Disord* 2012;140(2):113-24.

19. Leiser SC, Pehrson AL, Robichaud PJ, Sanchez C. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. *Br J Pharmacol* 2014;171(18):4255-72.
20. Li Y, Raaby KF, Sánchez C, Gulinello M. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. *Behav Brain Res* 2013;256:520-8.
21. Marshall K, Datta P, Rewers-Felkins K, Krutsch K, Baker T, Hale TW. Transfer of the Serotonin Modulator Vortioxetine into Human Milk: A Case Series. *Breastfeed Med* 2021;16(10):843-5.
22. McWilliams DF, Walsh DA. Pain mechanisms in rheumatoid arthritis. *Clin Exp Rheumatol* 2017;35 Suppl 107(5):94-101.
23. Monfort A, Jutras M, Martin B, Boucoiran I, Ferreira E, Leclair G. Simultaneous quantification of 19 analytes in breast milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS). *J Pharm Biomed Anal* 2021;204:114236.
24. Nicholson B, Verma S. Comorbidities in chronic neuropathic pain. *Pain Med* 2004;5 Suppl 1:S9-S27.
25. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. *J Clin Invest* 2010;120(11):3779-87.
26. Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. *J Psychiatr Res* 2015;64:88-98.
27. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. *Biol Psychiatry* 1999;45(9):1085-98.
28. Rakel RE. Depression. *Prim Care* 1999;26(2):211-24.
29. Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. *Rev Psiquiatr Salud Ment (Engl Ed)* 2018;11(1):48-59.
30. Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. *Pharmacol Rep* 2017;69(4):595-601.
31. Talmon M, Rossi S, Pastore A, Cattaneo CI, Brunelleschi S, Fresu LG. Vortioxetine exerts antiinflammatory and immunomodulatory effects on human monocytes/macrophages. *Br J Pharmacol* 2018;175(1):113-24.
32. Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. *Eur Neuropsychopharmacol* 2016;26(6):979-93.
33. Tomaz VS, Chaves Filho AJM, Cordeiro RC, Jucá PM, Soares MVR, Barroso PN, et al. Cristino LMF, Jiang W, Teixeira AL, de Lucena DF, Macedo DS. Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression. *J Affect Disord* 2020;268:188-200.
34. Yalcin I, Barthas F, Barrot M. Emotional consequences of neuropathic pain: insight from preclinical studies. *Neurosci Biobehav Rev* 2014;47:154-64.